This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-280292-90i45kjk | Acetaminophen( APAP) hepatotoxicity is n't it time for APAP to go away? |
| cord-003341-z5w56zeq | The case for the multifunctional NS3 protein from dengue virus as a target Strategies for development of dengue virus inhibitors Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control; World Health Organization Protective efficacy of the recombinant, live- attenuated, CYD tetravalent dengue vaccine in thai schoolchildren: A randomised, controlled phase 2b trial Dengue vaccine development: A 75% solution? |
| cord-280807-0g1uo0rd | -What is Missing? |
| cord-034363-6uscua0y | Beyond monoamines Pathophysiology of depression: Do we have any solid evidence of interest to clinicians? |
| cord-291180-xurmzmwj | Are we nearly there yet? |
| cord-254194-962vynwk | A hazardous threat to the environment and human health? |
| cord-254194-962vynwk | Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? |
| cord-284113-qboon2uv | How Different Are Their Essential Oil Profile and Antimicrobial Activity? |
| cord-276781-ujvkcz4s | what happened in the clinical trials and why might the drug have failed? |
| cord-287754-dh6abx2t | Galanthus nivalis agglutinin( GNA)-related lectins: Traditional proteins, burgeoning drugs? |
| cord-316474-407bthqj | Is there any pattern exists in propagationrelated TUPs? |
| cord-347992-coby2m6e | In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins Berzal- Herranz, A. RNA selection and evolution in vitro: powerful techniques for the analysis and identification of new molecular tools Aptamers: a new class of oligonucleotides in the drug discovery pipeline? |
| cord-355685-wgad0eoh | Towards prediction paradise? |
| cord-281281-knelqmzx | A fight for supremacy Type 1 interferons and the virus- host relationship: A lesson in détente Viruses and Interferons Recent insights into emerging coronaviruses Clinical characteristics of coronavirus disease 2019 in China Coronavirus infections and immune responses Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis Complement as a target in COVID-19? |
| cord-281281-knelqmzx | Should we stimulate or suppress immune responses in COVID-19? |
| cord-276598-tm0yj2sn | The tribological study of novel phosphorous- nitrogen type phosphoramidate additives in rapeseed oil Halogenated flame retardants: Do the fire safety benefits justify the risks? |
| cord-013412-gj443yei | Is antimicrobial resistance a slowly emerging disaster? |
| cord-013412-gj443yei | The G- Quadruplex/ Helicase World as a Potential Antiviral Approach against COVID-19 Targets and tools in antiviral therapy G- quadruplexes in pathogens: A common route to virulence control? |
| cord-013412-gj443yei | Type III Photochemical Mechanism? |
| cord-349672-2kt7xw8i | A Novel Candidate Gene in Juvenile Myoclonic Epilepsy? |
| cord-349672-2kt7xw8i | topoisomerase I conserved for interaction with a specific cytosine base to facilitate DNA cleavage Synthesizing topological structures containing RNA Type IA topoisomerases: A simple puzzle? |
| cord-287123-ldkuwcc7 | What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin a4? |
| cord-287123-ldkuwcc7 | What makes them special? |
| cord-281668-960trqex | Cathepsin L targeting in cancer treatment Cathepsin L, target in cancer treatment? |
| cord-281668-960trqex | The Future of Cysteine Cathepsins in Disease Management Cysteine proteases as therapeutic targets: Does selectivity matter? |
| cord-281668-960trqex | The first step towards selective irreversible inhibitors? 64) as Inhibitors of Cysteine Proteases |
| cord-344175-e2m9o8c2 | Angiotensin receptor blockers as tentative SARS- CoV-2 therapeutics Can chinese medicine be used for prevention of corona virus disease 2019( COVID-19)? |
| cord-344175-e2m9o8c2 | Developing new drugs or repurposing old ones? |
| cord-344175-e2m9o8c2 | Did ebola survivors use plant medicines, and if so, which ones? |
| cord-344175-e2m9o8c2 | Is there a hope from treatment with cardiovascular drugs? |
| cord-307731-a2fqmaly | 2020, 8, 246 Single- molecule pulling simulations can discern active from inactive enzyme inhibitors The light and dark sides of virtual screening: What is there to know? |
| cord-307731-a2fqmaly | An endless staircase? |
| cord-307731-a2fqmaly | How do small molecule aggregates inhibit enzyme activity? |
| cord-272465-i2l4cq8h | 1-trans- tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb- resistant non- small cell lung cancer via selectively elevating intracellular calcium level Autophagy in chronic obstructive pulmonary disease: Homeostatic or pathogenic mechanism? |
| cord-272465-i2l4cq8h | An"old- age"disease with an"age- old"solution Potential therapeutic effects of curcumin, the anti- inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? |
| cord-272465-i2l4cq8h | Can autophagy promote longevity? |
| cord-272465-i2l4cq8h | Loch ness monster or endangered species? |
| cord-334511-lx9608vy | : Is It Really$ 802 Million? |
| cord-334511-lx9608vy | How Much NMR Data Is Required to Determine a Protein- Ligand Complex Structure? |
| cord-334511-lx9608vy | Recent developments and new frontiers for targeting multi- protein complexes Screening protein- Single stranded RNA complexes by NMR spectroscopy for structure determination Intramolecularly stapled amphipathic peptides via a boron- sugar interaction Structure determination using solution NMR: Is it worth the effort? |
| cord-334511-lx9608vy | What Is the Question? |
| cord-334511-lx9608vy | Why not? |
| cord-309722-04pp3lv0 | : What's new? |
| cord-309722-04pp3lv0 | A review Influence of particle size on regional lung deposition- what evidence is there? |
| cord-309722-04pp3lv0 | An unsuccessful host defence mechanism providing a safety shelter for the bacteria? |
| cord-309722-04pp3lv0 | Delivering on the promise? |
| cord-309722-04pp3lv0 | How can we improve the therapeutic efficacy of RNAi in combating infections to make it clinically relevant? |
| cord-309722-04pp3lv0 | How can we minimize the undesirable effects when cytokines/ chemokines are being targeted? |
| cord-309722-04pp3lv0 | In Molecular Regulation of Endocytosis Nuclear entry of nonviral vectors Pulmonary administration of small interfering RNA: The route to go? |
| cord-309722-04pp3lv0 | RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription Barrier or carrier? |
| cord-309722-04pp3lv0 | When the respiratory functions are compromised in patients with lung disease, is pulmonary delivery a suitable route for administration? |
| cord-256838-8rzibpbl | A clue to Balkan endemic nephropathy? |
| cord-256838-8rzibpbl | Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids Is there an association between ephedra and heart failure? |
| cord-256838-8rzibpbl | Are these molecules specific for that specific activity of a TCM formula or herbs? |
| cord-256838-8rzibpbl | Could a specific ADR come from interactions between specific active molecules? |
| cord-256838-8rzibpbl | Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? |
| cord-256838-8rzibpbl | Could these activities be extrapolated into humans? |
| cord-256838-8rzibpbl | Could these inactive ingredients be omitted? |
| cord-256838-8rzibpbl | Could they reach a minimal serum level to exert that particular pharmacologic activity in humans? |
| cord-256838-8rzibpbl | Does publication bias exist so that undesired pharmacologic effects are not published? |
| cord-256838-8rzibpbl | Is it possible that a particular gene is prone to a specific ADR of a TCM formula or herbs? |
| cord-256838-8rzibpbl | Is it possible that herbs and TCM formulas can be effective in this low concentration of bioactive compounds? |
| cord-256838-8rzibpbl | Is it possible that interactions between active molecules, e.g., synergism, but not active molecules themselves, account for a specific activity? |
| cord-256838-8rzibpbl | Is it possible that little amount of bioactive molecules can cause interactions? |
| cord-256838-8rzibpbl | Is it possible that new active molecules are generated during preparation of the TCM formula? |
| cord-256838-8rzibpbl | Is it possible that the clinical effects of herbs and TCM formulas can be effective with such a small amount of bioactive compounds? |
| cord-256838-8rzibpbl | Is it possible that there might be unidentified active molecules that actually account for a particular pharmacologic activity? |
| cord-256838-8rzibpbl | Is there a specific gene or single nucleotide polymorphism( SNP) largely affecting the pharmacokinetic profile? |
| cord-256838-8rzibpbl | Positive or Negative Actors? |